SNaPshot for Pharmacogenetics by Minisequencing
Genetic polymorphisms of genes coding for metabolic enzymes are helpful to predict how an individual may respond to medication or drugs. The described approach for the identification of genetic variations for the cytochrome P450 enzymes CYP2D6 and CYP2C19 has been designed for the rapid genotyping of relevant alleles (CYP2D6**1, -**3, -**4, -**6, -**7, and -**8 and CYP2C19**1, -**2, -**3, -**4, and -**5) by performing polymerase chain reaction amplifications of genomic regions containing the SNP followed by a single-tube multiplex single base extension (minisquencing) reaction. This multiplex assay can easily be expanded for additional genes and single nucleotide polymorphisms (SNPs). Minisequencing is a sensitive, reproducible, and time-saving method for SNP typing that can be performed using ordinary laboratory equipment.
Key WordsSNPs pharmacogenetic CYP2D6 CYP2C19 minisequencing
- 9.Xiao, Z. S., Goldstein, J. A., Xie, H. G., Blaisdell, J., Wang, W., Jiang, C. H., et al. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the Smephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281, 604–609.PubMedGoogle Scholar
- 10.Ferguson, R. J., De Morais, S. M., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., et al. (1998) A new genetic defect in human CYP2C19 mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. JPET 284, 356–361.Google Scholar